lactococcus lactis

Cell therapyexperimental

Lactococcus lactis is a gram-positive bacterium used extensively in the production of buttermilk and cheese, but has also become famous as the first genetically modified organism to be used alive for the treatment of human disease. L. lactis cells are cocci that group in pairs and short chains, and, depending on growth conditions, appear ovoid with a typical length of 0.5 - 1.5 μm. L. lactis does not produce spores (nonsporulating) and are not motile (nonmotile). They have a homofermentative metabolism, meaning they produce lactic acid from sugars. They've also been reported to produce exclusive L-(+)-lactic acid. However, reported D-(−)-lactic acid can be produced when cultured at low pH. The capability to produce lactic acid is one of the reasons why L. lactis is one of the most important microorganisms in the dairy industry. Based on its history in food fermentation, L. lactis has generally recognized as safe (GRAS) status, with few case reports of it being an opportunistic pathogen. — Wikipedia

Clinical trial activity

12 trials · 25 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Apr 14, 2015 (NCT03528707)

Timeline

No events for the selected filters.

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • lactococcus lactis subsp. lactis ll358

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06650644N/AOct 10, 2024KoBioLabs, Korea University, Kyung Hee University
NCT05800704N/AMar 10, 2023Cantonal Hospital Winterthur, Luzerner Kantonsspital, Stadtspital Zürich, University of Basel, University of Bern, University of Zurich
NCT05632341N/ADec 20, 2022Green Cross Corporation
NCT04997057N/ASep 15, 2021CEN Biotech, Hopital Antoine Beclere, Pileje
NCT04659408N/AMar 1, 2021Swiss Paraplegic Centre Nottwil
NCT03959722N/AOct 31, 2019Hogeschool Leiden, University of Applied Sciences, Leiden University, University of Amsterdam, Wageningen University, Winclove Bio Industries BV
NCT04089280N/AOct 16, 2018Sanprobi Sp. z o.o., Silesian University of Medicine
NCT04201938N/AFeb 1, 2018Bogomolets National Medical University, Taras Shevchenko National University of Kyiv
NCT03220802N/ASep 22, 2017Medical University of Graz
NCT03300440N/AJun 21, 2017Medical University of Graz
NCT03066921N/AJun 1, 2016Tung's Taiching MetroHarbor Hospital
NCT03528707N/AApr 14, 2015Bogomolets National Medical University
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (25)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bogomolets National Medical UniversityAcademic/Hospital2212015
Medical University of GrazAcademic/Hospital2212017
Cantonal Hospital WinterthurAcademic/Hospital1012023
CEN BiotechFor profit1112021
Green Cross CorporationFor profit1112022
Hogeschool Leiden, University of Applied SciencesAcademic/Hospital1112019
Hopital Antoine BeclereAcademic/Hospital1012021
KoBioLabsFor profit1012024
Korea UniversityAcademic/Hospital1012024
Kyung Hee UniversityAcademic/Hospital1112024
Leiden UniversityAcademic/Hospital1012019
Luzerner KantonsspitalAcademic/Hospital1012023
PilejeAcademic/Hospital1012021
Sanprobi Sp. z o.o.For profit1012018
Silesian University of MedicineAcademic/Hospital1112018
Stadtspital ZürichAcademic/Hospital1012023
Swiss Paraplegic Centre NottwilAcademic/Hospital1112021
Taras Shevchenko National University of KyivAcademic/Hospital1012018
Tung's Taiching MetroHarbor HospitalAcademic/Hospital1112016
University of AmsterdamAcademic/Hospital1012019
25 organizations
Page 1 / 2